Factors Affecting the Price of Jaypirca

A summary of the drug's performance in clinical studies.

Clinical Outcomes

In the pivotal BRUIN trial for MCL patients previously treated with a BTK inhibitor, JAYPIRCA demonstrated an overall response rate (ORR) of 50%, with a median duration of response (DOR) of 8.3 months. For CLL/SLL patients previously treated with both a BTK and a BCL-2 inhibitor, the ORR was 72% with a median DOR of 12.2 months. These results supported the drug's accelerated approval, with continued approval potentially contingent upon verification of clinical benefit in confirmatory trials.

Related Columns

Pirtobrutinib(Jaypirca)

Treatment of relapsed or refractory mantle cell lymphoma (MCL) and chronic...

WeChat Scan
Free Inquiry

What are the purchase channels for Pirtobrutinib?

Pirtobrutinib is a targeted drug used to treat recurrent lymphoma. It has not yet been approved for marketing in mainland China. Patients need to obtain drugs through specific channels. The following ...

How much is Pirtobrutinib?

Pirtobrutinib is a new type of kinase inhibitor, mainly used to treat specific types of blood system diseases. At present, the drug has not been officially launched in China, but patients can pur...